 malign melanoma recombin interferon analysi consecut phase II investig phase II trial recombin interferon ifn patient biopsy-prov measur malign melanoma regimen number patient ifn-alpha subcutan SQ tiw patient ifn-alpha SQ tiw regimen patient ifn-alpha cimetidin immunorestor agent regimen patient ifn-gamma regimen patient ifn-alpha ifn gamma regimen patient ifn-alpha bis-chloroethylnitrosourea bcnu regimen patient ifn-alpha biochem modul difluoromethylornithin dfmo regimen patient object regress rate respons rate regimen surviv advantag program median time progress month median surviv time month regress soft tissu diseas partial month treatment patient ifn month durabl regress year alpha-regimen flu-typ ill anorexia dose-rel leukopenia noteworthi regimen gamma-interferon ongo trial altern improv immune-rel modal keen interest